Physician profile
Kyle A Baker
NPI 1922078948
$6,608.94
in general payments reported to CMS, 2019-2025
38 companies · $478 in 2025
The $478 reported for 2025 was more than what 79% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,055 · 2020: $748 · 2021: $1,160 · 2022: $1,056 · 2023: $1,190 · 2024: $922 · 2025: $478.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,490 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,490.44 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,387.32 | 2019-2025 | Lo Loestrin Fe, Orilissa, Liletta |
| Astellas Pharma US INC | $880.63 | 2019-2024 | Veozah, Myrbetriq |
| Exeltis, USA INC. | $548.47 | 2019-2025 | Slynd |
| Sumitomo Pharma America, INC. | $447.22 | 2023-2025 | Myfembree, Gemtesa |
| Coopersurgical, INC. | $359.12 | 2019-2025 | Paragard T 380a, Paragard T 380a |
| Agile Therapeutics, INC. | $318.62 | 2021-2024 | Twirla |
| Avion Pharmaceuticals | $308.99 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $233.80 | 2020-2024 | Gardasil 9, Gardasil |
| Therapeuticsmd, INC. | $212.47 | 2019-2022 | |
| Mayne Pharma Commercial LLC | $188.13 | 2021-2024 | |
| Lupin INC. | $158.71 | 2019-2021 | |
| Exact Sciences Corporation | $153.23 | 2023-2025 | Cologuard Collection Kit |
| Mylan Pharmaceuticals INC. | $139.00 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $135.78 | 2019-2025 | |
| Myovant Sciences INC. | $134.54 | 2021-2022 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $123.90 | 2019-2024 | |
| Organon LLC | $94.47 | 2022-2024 | |
| Amag Pharmaceuticals, INC. | $76.59 | 2019-2020 | |
| Urovant Sciences INC | $74.89 | 2021-2022 | |
| Duchesnay USA Incorporated | $71.24 | 2019 | |
| Sage Therapeutics, LLC | $70.41 | 2024-2025 | Zurzuvae |
| Millicent US INC | $69.54 | 2019-2025 | Femlyv |
| Aspira Women'S Health INC | $61.43 | 2019-2025 | Ova1 |
| Scynexis, INC. | $46.42 | 2022 | |
| Roche Diagnostics Corporation | $41.99 | 2019 | |
| Daiichi Sankyo INC. | $31.83 | 2023-2024 | Injectafer |
| Smith+Nephew, INC. | $27.04 | 2022 | |
| Allergan, INC. | $25.17 | 2019 | |
| Avanos Medical | $24.58 | 2019 | |
| Mission Pharmacal Company | $22.53 | 2023 | Citranatal |
| Ge Healthcare | $21.75 | 2025 | |
| Boston Scientific Corporation | $20.60 | 2024 | Solyx Sis System |
| Supernus Pharmaceuticals, INC. | $19.73 | 2025 | Qelbree |
| Medtronic, INC. | $18.69 | 2025 | Closurefast |
| Conmed Corporation | $18.43 | 2025 | Airseal |
| Evofem Biosciences, INC. | $16.81 | 2020 | |
| Monaghan Medical Corporation | $13.15 | 2023 | Aeroeclipse |
| Hologic Sales and Service, LLC | $11.72 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.